Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors

Haemophilia

Volumn 21, Issue 3, 2015, Pages 358-364

  Ewing, N ^a   Escuriola Ettingshausen, C ^b   Kreuz, W ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b HZRM Hemophilia Centre Rhein Main   (Germany)

Author keywords

FEIBA; FVIII inhibitor; Haemophilia A; Paediatric; Prophylaxis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; ALLOANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING INHIBITOR;

ARTICLE; CHILD; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DEMOGRAPHY; FEMALE; FLEXION CONTRACTURE; HEMOPHILIA; HEMOPHILIA A; HOSPITALIZATION; HUMAN; IMMUNOLOGICAL TOLERANCE; LONG TERM CARE; MALE; MEDICAL RECORD; MEDICAL RECORD REVIEW; MUSCLE ATROPHY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; SEROCONVERSION; BLOOD; COMPLICATION; GERMANY; HEMARTHROSIS; IMMUNOLOGY; INFANT; PREMEDICATION; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; FACTOR VIII; GERMANY; HEMARTHROSIS; HEMOPHILIA A; HUMANS; INFANT; ISOANTIBODIES; PREMEDICATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84928829654     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12602     Document Type: Article

References (42)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
2. Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65: 129-35.
3. Hoots WK, Nugent DJ. Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 2006; 96: 433-40.
4. Tagliaferri A, Franchini M, Coppola A, Rivolta GF, Santoro C, Rossetti G, et al. Effects of secondary prophylaxis started in adolescent and adult hae-mophiliacs. Haemophilia 2008; 14: 945-51.
5. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients-a long-term follow-up. J Intern Med 1997; 241: 395-400.
6. Biss TT, Chan AK, Blanchette VS, Iwenofu LN, McLimont M, Carcao MD. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 2008; 14: 923-30.
7. Carlsson KS, Hojgard S, Glomstein A et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 9: 555-6.
8. Hay CR. The epidemiology of factor VIII inhibitors. Haemophilia 2006; 12(Suppl 6): 23-8; discussion 8-9.
9. DiMichele D, Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
10. Gomperts E. FEIBA safety and tolerability profile. Haemophilia 2006; 12: 14-9.
11. Tjonnfjord GE, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Vasc Health Risk Manag 2007; 3: 527-31.
12. Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009; 15: 904-10.
13. Astermark J, Rocino A, Von Depka M et al. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 2007; 13: 38-45.
14. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.
15. Siegmund B, Richter H, Pollmann H. Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits? Haemophilia 2005; 11: 638-41.
16. Valentino LA. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia 2009; 15: 733-42.
17. Valentino LA. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia 2010; 16: 263-71.
18. Carcao M, Lambert T. Prophylaxis in haemophilia with inhibitors: update from international experience. Haemophilia 2010; 16(Suppl 2): 16-23.
19. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007; 13: 249-55.
20. Ohga S, Nomura A, Takada H, Suga N, Hara T. Successful self-infusion of activated prothrombin complex concentrate for prophylaxis in a child with a factor VIII inhibitor. Am J Hematol 2007; 82: 145-9.
21. Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008; 14(Suppl 6): 20-2.
22. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
23. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154-62.
24. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years' 'bonn protocol'. Vox Sang 1996; 70(Suppl 1): 30-5.
25. Kreuz W, Escuriola-Ettingshausen C, Mentzer D. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors. Blood 2000; 96: 266a.
26. Hilgartner MW, Makipernaa A, Dimichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003; 9: 261-8.
27. Ettingshausen CE, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: a prospective clinical case series. Haemophilia 2010; 16: 90-100.
28. Jimenez-Yuste V, Alvarez MT, Martin-Salces M et al. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia 2009; 15: 203-9.
29. Valentino LA. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia 2010; 16: 263-71.
30. Valentino L. FEIBA Prophylaxis in Hemophilia A Patients with Inhibitors Results in a 95% Reduction in Bleeding Episodes. Haemophilia 2004; 10: 113-6 s3.
31. Saxena KHS, Stevens B, Sexauer C. Long-term clinical experience with FEIBA VH in hemophilia patients with inhibitors. J Thromb Haemost 2005; 3: P0838.
32. Perry D, Berntorp E, Tait C et al. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations. Haemophilia 2010; 16: 80-9.
33. Leissinger C, Gringeri A, Antmen B et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-92.
34. Antunes SV, Tangada S, Stasyshyn O et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014; 20: 65-72.
35. Ljung R. Paediatric care of the child with haemophilia. Haemophilia 2002; 8: 178-82.
36. Hill FG, Ljung R. Third and fourth Workshops of the European Paediatric Network for Haemophilia Management. Haemophilia 2003; 9: 223-8.
37. Ewing N. Anamnestic responses in hemophilia patients with inhibitors on continuous prophylaxis with factor eight inhibitor bypassing activity, vapor heated (FEIBA VH). J Thromb Haemost 2005; 3: P2036.
38. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
39. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999; 5(Suppl 3): 25-32.
40. National Hemophilia Foundation. MASAC recommendation concerning prophylaxis (Regular administration of clotting factor concentrate to prevent bleeding). 2007; http://www.hemophilia.org/sites/default/files/document/files/masac179.pdf.
41. Valentino LA, Carcao M, Mathew P et al. The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report. Haemophilia 2009; 15: 959-65.
42. Teitel J, Berntorp E, Dolan G et al. A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients. Haemophilia 2011; 17: 516-21.